Efficacy, Durability, And Retreatment Outcomes Of Risankizumab In Moderate To Severe Plaque Psoriasis: Results From The Phase 3 Immhance Trial

Abstract

Psoriasis is a psychosocially and clinically burdensome, chronic immune-mediated inflammatory disorder. Risankizumab is a humanized monoclonal antibody against the interleukin-23 (IL 23) p19 subunit, and has been found to be highly effective in plaque psoriasis. The IMMhance trial was a phase 3, 2 year, randomized, placebo-controlled, and double-blind trial assessing the effectiveness, maintenance and retreatment of risankizumab in patients with moderate and severe psoriasis of the plaque. The patients were given risankizumab or placebo over a 16-week phase after which they were given maintenance, withdrawal and also retreatment. Risankizumab at week 16 had much higher levels of PASI 90 and sPGA 0/1 response levels as compared to placebo. Prolonged therapy up to week 104 ensured clinical response, but the withdrawal of the treatment contributed to the gradual relapse of the disease. Notably, the disease control was restored successfully as a result of retreatment. In general, risankizumab showed a long-term efficacy, good durability, and stability, which justifies its use in the long run in moderate to severe plaque psoriasis.